Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)‐derived peptides immunogenic in HLA‐A24+ prostate cancer patients

Antigens overexpressed in metastatic prostate cancer are appropriate targets in anti‐cancer immunotherapy, and one candidate is the polycomb group protein enhancer of zeste homolog 2 (EZH2).

[1]  S. Senju,et al.  Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin‐like protein, originally defined by the SEREX method , 2002, European journal of immunology.

[2]  H. Ragde,et al.  Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides , 1998, The Prostate.

[3]  M. Peshwa,et al.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Yamana,et al.  Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre‐existing cellular response to peptide , 2003, Cancer science.

[5]  Y. Iwamoto,et al.  In Vivo Evidence That Peptide Vaccination Can Induce HLA-DR-Restricted CD4+ T Cells Reactive to a Class I Tumor Peptide 1 , 2004, The Journal of Immunology.

[6]  H. Takasu,et al.  A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation , 2002, Cancer Immunology, Immunotherapy.

[7]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[8]  S. Steinberg,et al.  Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer , 2002, The Prostate.

[9]  R. DePinho,et al.  The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus , 1999, Nature.

[10]  K. Kato,et al.  Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. , 2001, The Journal of urology.

[11]  K. Itoh,et al.  Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccination , 2003, The Prostate.

[12]  K. Itoh,et al.  Prostate‐specific antigen‐derived epitopes capable of inducing cellular and humoral responses in HLA‐A24+ prostate cancer patients , 2003, The Prostate.

[13]  C. Nislow,et al.  Mammalian homologues of the Polycomb‐group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S.cerevisiae telomeres , 1997, The EMBO journal.

[14]  K. Shirouzu,et al.  Immunological evaluation of CTL precursor‐oriented vaccines for advanced lung cancer patients , 2003, Cancer science.

[15]  K. Itoh,et al.  Identification of a prostate‐specific membrane antigen‐derived peptide capable of eliciting both cellular and humoral immune responses in HLA‐A24+ prostate cancer patients , 2003, Cancer science.

[16]  K. Itoh,et al.  Target molecules in specific immunotherapy against prostate cancer , 2003, International Journal of Clinical Oncology.

[17]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[18]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[19]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Nukiwa,et al.  IgG reactive to CTL-directed epitopes of self-antigens is either lacking or unbalanced in atopic dermatitis patients. , 2003, Tissue antigens.

[21]  H. Ragde,et al.  Infusion of dendritic cells pulsed with HLA‐A2‐specific prostate‐specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone‐refractory metastatic disease , 1999, The Prostate.

[22]  K Kornfeld,et al.  Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. , 1999, Genes & development.

[23]  H. Yamana,et al.  Peptide Vaccination for Patients With Melanoma and Other Types of Cancer Based on Pre-existing Peptide-Specific Cytotoxic T-Lymphocyte Precursors in the Periphery , 2003, Journal of immunotherapy.

[24]  T. Nukiwa,et al.  Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals. , 2002, Tissue antigens.

[25]  K. Ushijima,et al.  Vaccination with Predesignated or Evidence-Based Peptides for Patients with Recurrent Gynecologic Cancers , 2004, Journal of immunotherapy.

[26]  G. Murphy,et al.  Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigen , 1996, The Prostate.